Controversial impact factor gets a heavyweight rival

An IPO’s Impact on Rival Firms

We would like to thank seminar participants at Yeshiva University for helpful discussions.

Factor VIIa gets even bigger.

Thromb Haemost 2008; 99: 653–654 Since its introduction onto the market in 1996, recombinant factor VIIa (rFVIIa: NovoSeven®; Niastase®; produced by Novo Nordisk, Baegsvaerd, Denmark) has become an increasingly important therapeutic option for physicians caring for haemophilia patients with inhibitors. Both because of its short terminal half-life of approximately three hours (1, 2), and the way...

Heavyweight Class

tion among the heavyweights, with the recent newcomer Fundamental Neuroscience tipping the scales at 1600 pages. to produce it, and the Duke certainly has his modern seizure activity (Westbrook). Virtually all the authors are counterparts. " I hate textbooks, " announced a recent well recognized experts in their fields, assuring quality reviewer of another large neuroscience textbook. " The cov...

The Perception Factor: Climate Change Gets Personal

Super factor B-gets atypical HUS.

a common ligand with GPVI and requires previous activating signals to adopt a high-affinity conformation needed for colla-gen adhesion. Mazzucato et al make an important contribution by showing that, as platelets interact with collagen under flow, ␣2␤1 receptors generate calcium signals that are distinct from those generated by GPVI. Surprisingly, ␣2␤1-dependent calcium signals are even generat...